Background/Aims: MicroRNAs (miRNAs) have emerged as major regulators of tumour development and progression in non-small cell lung cancer (NSCLC). However, the role of miR-193a-3p in NSCLC is still unclear. Methods: Quantitative RT-PCR was used to detect miR-193a-3p expression levels in NSCLC tumour tissues. CCK8, EdU and cell migration assays were performed to analyse the biological functions of miR-193a-3p in NSCLC cells. Luciferase reporter assays were used to validate the bioinformatics-predicted target genes of miR193a-3p. Western blotting and RNA/DNA interference carried out to evaluate the association between miR-193a-3p and KRAS. Results: miR-193a-3p expression was decreased in the NSCLC tumour tissues. We investigated the biological effects of miR-193a-3p both in vivo and in vitro and found that enforced expression of miR-193a-3p inhibited tumour formation and suppressed cell proliferation and cell migration. KRAS was found to be a potential target of miR-193a-3p, and dual luciferase reporter assays showed that miR-193a-3p directly binds to the 3'-untranslated region (3'-UTR) of KRAS mRNA. In addition, we found that changing the expression of KRAS had the opposite results to those induced by miR-193a-3p in the NSCLC cells. Importantly, simultaneous overexpression of miR-193a-3p and KRAS could counteract the effects of both on cellular functions. Conclusion: role for miR-193a-3p as a tumour suppressor in NSCLC pathogenesis via the regulation of KRAS expression.
MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS
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Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for the majority (75-80%) of lung cancer cases [1] . Although NSCLC has been investigated in numerous molecular studies aimed at developing new treatment strategies, the 5-year overall survival rate remains < 15% [2] . The exact mechanisms underlying oncogenesis and development of NSCLC remain complex and therapeutic targets for this disease are urgently needed.
MicroRNAs (miRNAs) are a class of endogenous, small, noncoding RNAs that are highly carcinogenesis and cancer progression [5, 6] . In mammals, miRNAs bind to complementary sites at the 3'-untranslated regions (3'-UTRs) of their targeted mRNAs, thereby inhibiting translation or favouring the destabilization of mRNAs, depending on the degree of nucleotide pairing. Anomalous miRNAs can exert a major effect by suppressing oncogenes or tumour suppressors, thereby functioning as tumour-suppressive miRNAs or oncogenic miRNAs during carcinogenesis. In past decade, the therapeutic potential of miRNAs in cancer has been demonstrated in an enormous number of published studies, including studies of NSCLC [7] [8] [9] . miR-193a, which consists of miR-193a-3p and miR-193a-5p, is one of the miRNAs involved in carcinogenesis. miR-193a-3p plays essential roles in the multi-chemoresistance of bladder cancer [10] , epithelial ovarian cancer [11] , breast cancer [12] , colorectal cancer [13] and lung cancer [14] . However, although several studies indicating that miR-193a-3p is closely related to tumourigenesis have been published, the detailed roles of miR-193a-3p in the initiation and progression of NSCLC remain largely unknown. The aim of this study was to investigate the association between miR-193a-3p expression and NSCLC and to explore potential novel target genes of miR-193a-3p.
In this study, we demonstrated that miR-193a-3p levels were consistently downregulated in NSCLC tissues. We showed that miR-193a-3p inhibited tumour growth in an NSCLC cancer and found that miR-193a-3p might inhibit the viability, proliferation and migration of NSCLC cells by directly targeting a critical oncogene, KRAS.
Materials and Methods

Human tissues and cell lines
A total of 8 pairs of NSCLC tissues (LC) and matched noncancerous tissues (LN) were obtained from patients who underwent a surgical procedure at the Tianjin Medical University Cancer Institute and Hospital (Tianjin, China). The tissues were immediately frozen in liquid nitrogen and stored at -80°C. The clinical features of the NSCLC patients are listed in mouse every other day for a total of 6 doses. Tumour volumes were assessed by BLI on days 14 and 28. The luminescence index from the 5 mice in each group were averaged. On day 28, the mice were euthanized. The tumour xenografts were removed, parts of the tumours were used for protein and total RNA extraction, and staining and immunohistochemical staining for Ki-67.
miR-193a-3p overexpression or knockdown miRNA overexpression was achieved by transfecting cells with a pre-miR-193a-3p, whereas knockdown was achieved by transfecting cells with an anti-miR-193a-3p. Synthetic pre-miR-193a-3p, anti-miR-193a-were seeded in 6-well plates and were transfected using Lipofectamine 3000 (Invitrogen) according to the manufacturer's guidelines. In each well, 100 pmol pre-miR-193a-3p, anti-miR-193a-3p, or scrambled harvested 48 h after transfection for Western blotting.
RNA isolation and quantitative RT-PCR
Total RNA was isolated according to the manufacturer's instructions using TRIzol reagent (Invitrogen). Assays to quantify mature miRNAs were performed using TaqMan miRNA probes (Applied Biosystems, quantify miRNA levels and mRNA levels (see our previous study for details [15] Cell viability assay For determination of cell viability, 6 h after transfection, A549 and H1975 cells were seeded in triplicate in 96-well plates at a density of 1 × 10 4 transfection according to the manufacturer's instructions.
EdU proliferation assay A549 cells were seeded into 48-well plates to assess cell proliferation. The cells were incubated under standard conditions in complete media (DMEM supplemented with 10% FBS). Transfection of the cells and cell harvesting were performed the following day as described above. Cell proliferation was detected by and EdU staining, which were performed according to the manufacturer's protocol. The cell nuclei were stained with Hoechst (RiboBio, Guangzhou, China). The proportion of nucleated cells incorporating EdU
Cell migration assay
The migration of A549 and H1975 cells were tested using a two-chamber Transwell cell migration 4 2 atmosphere that was saturated with H 2 O at 37°C. After incubation, cells in the upper surface of the Transwell chamber were removed using cotton swabs.
with crystal violet solution (0.5% in methanol) for 15 min at room temperature. The lower surfaces (with Japan).
miRNA target prediction
Genes that may be targeted by miR-193a-3p were determined using three computational algorithms,
Luciferase reporter assay
For analysis of the direct binding of miR-193a-3p to the target gene KRAS, a luciferase reporter assay was performed as previously described [16] that interacted with the miR-193a-3p seed sequence were mutated (both binding positions were mutated).
siRNA and plasmid construction interference assay (Shanghai, China). The siRNA sequence was 5'-GGAAGCAAGUAGUAAUUGATT-3'. The scrambled siRNA was included as a negative control. A mammalian expression plasmid (pReceiver-M02-KRAS) was purchased from GeneCopoeia (Germantown, MD, USA). An empty plasmid (pReceiver-M02) served as a negative control. The KRAS siRNA or KRAS overexpression plasmid was transfected into A549 and H1975 cells using Lipofectamine 3000 (Invitrogen) according to the manufacturer's instructions. Total RNA or protein was KRAS mRNA and protein levels, respectively.
Protein isolation and Western blotting
buffer containing the protease and phosphatase inhibitor cocktail on ice for 60 min. When necessary, sonication was used to facilitate cell lysis. Cell lysates or tissue homogenates were centrifuged for 15 min (12, 000 g, 4°C). The supernatant was collected, and the protein concentration was calculated using a Western blotting with the corresponding antibodies. Densitometry analysis was performed using ImageJ
Statistical analysis
All Western blotting images are representative of at least three independent experiments. Quantitative in triplicate, and each experiment was repeated at least 3 times. Data (mean ± SEM) are representative of at least three independent experiments. The numerical data were statistically analysed by two-tailed Student's 
Results
miR-193a-3p is downregulated in NSCLC tissues
We assessed the expression patterns of miR-193a-3p in 8 NSCLC tissues and 8 normal adjacent tissues using quantitative miR-193a-3p levels were found to be consistently downregulated in NSCLC tissues compared to normal adjacent tissues (Fig.  1) .
miR-193a-3p functions as a tumour suppressor in NSCLC
Then, we evaluated the biological effects of miR-193a-3p on NSCLC tumourigenesis in a xenograft mouse model. A549-Luc cells were subcutaneously implanted into 6-week-old SCID mice; after 14 days, the transplanted nude mice were randomly 3p was directly injected into the implanted tumour every other day for a total of six doses, and tumour volumes were assessed by BLI. The luminescence index from the 5 mice in each group was averaged. The fold increase in BLI was calculated as the proportion of post-treat--ton count of the tumours was observed in the Chol-miR-193a-3p-treated group compared from each xenograft and used to evaluate the expression of miR-193a-3p. After two weeks of intratumoural treatment, tumours from the Chol-miR-193a-3p-treated group showed a -Chol-miR-NC-treated groups (Fig. 2D) . Finally, the proliferative activity of the tumour cells was assessed via immunohistochemical staining of Ki-67. The tumour cell proliferation rate, as measured by the staining intensity of Ki-67-positive cells, was reduced in tumours from the Chol-miR-193a-3p-treated group (Fig. 2E and 2F) .
Effect of miR-193a-3p in the regulation of proliferation, viability and migration of NSCLC cells
We investigated whether miR-193a-3p overexpression or knockdown would impact the functions of NSCLC cells. In these experiments, miR-193a-3p was overexpressed by more than 100-fold following transfection of the A549 or H1975 NSCLC cell lines with premiR-193a-3p, and miR-193a-3p knockdown reduced expression by approximately 50% overexpression or knockdown of miR-193a-3p in A549 and H1975 cells is shown in (Fig. 3A) . The proliferation of A549 cells, as measured by the percentage of EdU-positive cells in the EdU assay, was decreased approximately 40% in A549 cells transfected with pre-miR-193a-3p; by contrast, knockdown of miR-193a-3p had the opposite effect on A549 cell proliferation ( Fig. 3B and 3C ). Moreover, cell viability was investigated via CCK8 assays. Overexpression of miR-193a-3p suppressed the viability of A549 and H1975 cells, while inhibition of miR193a-3p increased cell viability ( Fig. 3D and 3E ). Furthermore, we analysed the effects of miR-193a-3p on the migration of A549 and H1975 cells using Transwell assays. As expected, cells transfected with pre-miR-193a-3p showed a reduction in cell motility, whereas the cells transfected with anti-miR-193a-3p showed enhanced cell motility ( Fig. 3F and 3G ).
Prediction of KRAS as a target gene of miR-193a-3p
To explore the molecular mechanism by which miR-193a-3p contributes to the tumour suppression of NSCLC, we used three publicly available algorithms, including TargetScan  [17] [18] and miRanda [19] , in combination to search for potential targets of miR- 193a-3p. Among the candidates, KRAS, an oncogene that is frequently upregulated in NSCLC, was predicted to be a miR-193a-3p target by all three of the algorithms and was selected the target site in the KRAS 3'-UTR is shown in Fig. 4A . Two predicted hybridizations were observed between miR-193a-3p and the 3'-UTR of KRAS. The minimum free energy values of the two hybridizations between miR-193a-3p and KRAS are -16.7 and -22.4 kcal/mol, which are well within the range of genuine miRNA-target pairs. Theoretically, miRNAs are believed to have expression patterns that are opposite to those of their targets [20, 21] . We next investigated whether miR-193a-3p was inversely correlated with KRAS in NSCLC tissues. We measured the expression pattern of KRAS in the same 8 pairs of NSCLC tissues and normal adjacent tissues. KRAS protein levels were consistently increased in NSCLC tissues ( Fig. 4B and 4C ). In contrast, KRAS mRNA levels did is consistent with the involvement of a post-transcriptional mechanism in the regulation of KRAS. The inverse correlation between miR-193a-3p and KRAS protein levels (Fig. 4E ) and the disparity between the miR-193a-3p and KRAS mRNA levels (Fig. 4F) were further in tumours from the xenograft mice. Tumours from the Chol-miR-193a-3p-treated group displayed reduced KRAS protein levels ( Fig. 4G and 4H ), but not mRNA levels, compared based on both computational predictions and the inverse correlation between miR-193a-3p and KRAS protein levels, but not mRNA levels, in NSCLC tissues.
Validation of KRAS as a direct target of miR-193a-3p
The correlation between miR-193a-3p and KRAS expression was further investigated by evaluating KRAS expression in A549 and H1975 NSCLC cell lines after overexpression or knockdown of miR-193a-3p. The expression of KRAS protein was reduced approximately 50% by miR-193a-3p overexpression and increased by miR-193a-3p knockdown in A549 and H1975 cells (Fig. 5A and 5B). To determine the level at which miR-193a-3p regulates KRAS expression, we repeated the above experiments and examined the expression of KRAS mRNA after transfection. Overexpression or knockdown of miR-193a-3p did not affect the (Fig. 5D) . 
Role of miR-193a-3p in regulating NSCLC cell function by inhibiting KRAS
Subsequently, we investigated whether miR-193a-3p inhibits NSCLC tumourigenesis by silencing KRAS. We assessed the role of KRAS on cell function after overexpression or demonstrated in Fig. 6A-6C . As anticipated, transfection with KRAS siRNA markedly decreased the cell viability compared to the cells transfected with control siRNA, whereas transfection with the KRAS-overexpression plasmid increased cell viability (Fig. 6D) . Transfection with KRAS siRNA markedly decreased the percentage of proliferative EdU-positive cells, whereas transfection with the KRAS-overexpression plasmid increased cell proliferation (Fig. 6E and  6F) . Additionally, transfection with KRAS siRNA dramatically reduced the number of A549 cells that passed through the Transwell membrane, whereas transfection with the KRAS overexpression plasmid increased the migration rate ( Fig. 6G and 6H) . Because miR-193a-3p and its target KRAS had opposite expression patterns and biological functions in NSCLC cells, miR-193a-3p may inhibit NSCLC tumourigenesis by silencing KRAS. To investigate whether miR-193a-3p regulation of cell function is mediated through a KRAS-dependent mechanism, we co-transfected A549 cells with pre-miR-193a-3p and the KRAS-overexpression plasmid. After co-transfection with pre-miR-193a-3p and the compared with the cells transfected with pre-miR-193a-3p alone (Fig. 7A and 7B) , suggesting that miR-193a-3p-resistant KRAS can attenuate the proliferative effect of miR-193a-3p on A549 cells. Similarly, compared with the cells transfected with pre-miR-193a-3p alone, the cells co-transfected with pre-miR-193a-3p and the KRAS-overexpression plasmid attenuated the inhibitory effect of miR-193a-3p on cell viability (Fig. 7C) . In addition, co-transfection with pre-miR-193a-3p and the KRAS-overexpression plasmid dramatically attenuated the inhibitory effect of miR-193a-3p on cell migration (Fig. 7D and 7E ). Taken together, these results indicate that miR-193a-3p may regulate the proliferation, viability and migration of NSCLC cells in a KRAS-dependent manner.
Discussion
For the past decade, the study of miRNAs has grown exponentially. Furthermore, it has become clear that aberrant miRNA expression levels are associated with tumour formation, treatment. The rationale for miRNA replacement therapy is that miRNAs play a causative role in tumourigenesis of cancer [22] can function as either a tumour suppressor or an oncogene. Accordingly, miRNAs can also serve as either biomarkers or therapeutic targets in cancer treatments [23] .
Lung cancer is the major cause of cancer morbidity and mortality worldwide. Chemotherapy is the main treatment for lung cancer, and drug resistance is a major problem miRNAs, as novel biomarkers and tools for treatment of NSCLC [24] . A single miRNA can target multiple genes, whereas multiple miRNAs can target a single gene. Recently, miRNA regulatory mechanisms that are dysfunctional in lung cancer have been reported [25] [26] [27] .
or animal models of cancer [28, 29] . The development of miRNA-targeted therapeutics has become an important anticancer strategy. miR-193a-3p, one of the best-known miRNAs involved in carcinogenesis, is correlated with a wide variety of cellular processes, such as cell differentiation, apoptosis, proliferation, migration and cell-cycle distribution. miR-193a-3p also plays vital roles in several types of human cancers, including lung cancer [30] , and miR-193a-3p was reported to function as a tumour suppressor in lung cancer through the inhibition of ERBB4 translation [31] .
In this study, we evaluated the expression patterns of miR-193a-3p in NSCLC tissues and that miR-193a-3p is downregulated in NSCLC prompted us to hypothesize that miR-193a-3p might play an important role in NSCLC carcinogenesis. Consistent with this hypothesis, some studies have found that miR-193a-3p can function as a tumour suppressor in lung cancer [31, 32] . To illustrate this, we used an intratumoural injection of Chol-miR-193a-3p as an "miRNA replacement therapy". As expected, the size of tumours decreased in the Chol-miR-KRAS as a direct target. The results indicated that overexpression of miR-193a-3p may be involved in the progression of the NSCLC by targeting KRAS in this malignant tumour. In future studies, the clinical implications of the expression of miR-193a-3p in cancer tissues should be evaluated. Activating mutations turn KRAS into one of the most prevalent oncogenes, but an effective drug targeting mutated KRAS has not yet been developed. Since Johnson et al, [8] , legions of studies have [35] . In this study, we observed that KRAS was consistently overexpressed in NSCLC tissues compared with normal adjacent tissues. We also demonstrated that KRAS functions as an essential pro-proliferation factor in NSCLC; silencing KRAS expression in NSCLC cells through siRNA inhibited cell viability, proliferation and migration, whereas overexpressing KRAS strongly between KRAS protein and mRNA levels in human NSCLC tissues, suggesting that a posttranscriptional regulatory mechanism is involved in KRAS repression. Because miR-193a-3p is an upstream regulator of KRAS, restoration of miR-193a-3p expression may suppress KRAS in vivo. Further studies are needed to characterise the feasibility of targeting miR-193a-3p in Taken together, this study delineated a critical role of miR-193a-3p as a tumour suppressor in NSCLC and found that miR-193a-3p can directly regulate KRAS. Regulation of KRAS by miR-193a-3p may be one of the reasons why the downregulation of miR-193a-3p during NSCLC carcinogenesis promotes tumour growth. In the future, personalized cancer potential novel avenue for future NSCLC therapy.
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